Statins have been widely used for the treatment of hypercholesterolemia due to their ability to inhibit HMG-CoA reductase, the rate-limiting enzyme of de novo cholesterol synthesis, via the so-called mevalonate pathway. However, their inhibitory action also causes depletion of downstream intermediates of the pathway, resulting in the pleiotropic effects of statins, including the beneficial impact in the treatment of cancer. In our study, we compared the effect of all eight existing statins on the expression of genes, the products of which are implicated in cancer inhibition and suggested the molecular mechanisms of their action in epigenetic and posttranslational regulation, and in cell-cycle arrest, death, migration, or invasion of the cancer cells.

Department of Biochemistry and Microbiology University of Chemistry and Technology Prague Technická 3 166 28 Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics and 4th Department of Internal Medicine 1st Faculty of Medicine Charles University 128 08 Prague Czech Republic

Institute of Medical Biology Genetics and Clinical Genetics Faculty of Medicine Comenius University Špitálska 24 813 72 Bratislava Slovakia

Laboratory of Genomics and Bioinformatics Institute of Molecular Genetics Czech Academy of Sciences Vídeňská 1083 142 20 Prague Czech Republic

Zobrazit více v PubMed

Goldstein J.L., Brown M.S. A century of cholesterol and coronaries: From plaques to genes to statins. Cell. 2015;161:161–172. doi: 10.1016/j.cell.2015.01.036. PubMed DOI PMC

Alexandrova R., Dinev D., Glavcheva M., Danova J., Yetik-Anacak G., Krasilnikova J., Podlipnik C. Briefly about anticancer properties of statins. Biomed. J. Sci. Tech. Res. 2019;7:12655–12659. doi: 10.26717/BJSTR.2019.17.002975. DOI

Mohammadkhani N., Gharbib S., Rajani H.F., Farzaneh A., Mahjoobe G., Hoseinsalari A., Korsching E. Statins: Complex outcomes but increasingly helpful treatment options for patients. European J. Pharmacol. 2019;863:1–8. doi: 10.1016/j.ejphar.2019.172704. PubMed DOI

Tavintharan S., Ong C.N., Jeyaseelan K., Sivakumar M., Lim S.C., Sum C.F. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: A possible role in statin-induced hepatotoxicity? Toxicol. Appl. Pharmacol. 2007;223:173–179. doi: 10.1016/j.taap.2007.05.013. PubMed DOI

Svoboda M., Vyskočil J., Nováková J. Statiny v onkologii. Klin. Farmakol. Farm. 2005;19:155–159.

Newman T.B., Hulley S.B. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55–60. doi: 10.1001/jama.1996.03530250059028. PubMed DOI

Dalen J.E., Dalton W.S. Does lowering cholesterol cause cancer? JAMA. 1996;275:67–69. doi: 10.1001/jama.1996.03530250071030. PubMed DOI

Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med. 1996;335:1001–1009. doi: 10.1056/NEJM199610033351401. PubMed DOI

Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M., Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–1622. doi: 10.1001/jama.279.20.1615. PubMed DOI

Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., Guchelaar H.J. The risk of cancer in users of statins. Am. J. Clin. Oncol. 2004;22:2388–2394. doi: 10.1200/JCO.2004.02.027. PubMed DOI

Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. doi: 10.1016/S0140-6736(94)90566-5. PubMed DOI

Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995;333:1301–1307. doi: 10.1056/NEJM199511163332001. PubMed DOI

Lewis S.J., Sacks F.M., Mitchell J.S., East C., Glasser S., Kell S., Letterer R., Limacher M., Moye L.A., Rouleau J.L., et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) trial. J. Am. Coll. Cardiol. 1998;32:40–46. doi: 10.1016/S0735-1097(98)00202-2. PubMed DOI

Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation. 1998;98:839–844. doi: 10.1161/01.CIR.98.9.839. PubMed DOI

Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998;339:1349–1357. doi: 10.1056/NEJM199811053391902. PubMed DOI

Athyros V.G., Papageorgiou A.A., Mercouris B.R., Athyrou V.V., Symeonidis A.N., Basayannis E.O., Demitriadis D.S., Kontopoulos A.G. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr. Med. Res. Opin. 2002;18:220–228. doi: 10.1185/030079902125000787. PubMed DOI

Khurana V., Bejjanki H.R., Caldito G., Owens M.W. Statins reduce the risk of lung cancer in humans: A large case-control study of US Veterans. Chest. 2007;131:1282–1288. doi: 10.1378/chest.06-0931. PubMed DOI

Kochhar R., Khurana V., Bejjanki H., Caldito G., Fort C. Statins reduce breast cancer risk: A case control study in US female veterans. J. Clin. Oncol. 2005;23:514. doi: 10.1200/jco.2005.23.16_suppl.514. DOI

Singal R., Khurana V., Caldito G., Fort C. Statins and prostate cancer risk. J. Clin. Oncol. 2005;23:1004. doi: 10.1200/jco.2005.23.16_suppl.1004. DOI

Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., Low M., Greenson J.K., Rennert G. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005;352:2184–2192. doi: 10.1056/NEJMoa043792. PubMed DOI

Kawata S., Nagase T., Yamasaki E., Ishiguro H., Matsuzawa Y. Modulation of the mevalonate pathway and cell growth by pravastatin and dlimonene in a human hepatoma cell line (Hep G2) Br. J. Cancer. 1994;69:1015–1020. doi: 10.1038/bjc.1994.199. PubMed DOI PMC

Hawk M.A., Cesen K.T., Siglin J.C., Stoner G.D., Ruch R.J. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett. 1996;109:217–222. doi: 10.1016/S0304-3835(96)04465-5. PubMed DOI

Feleszko W., Jakobisiak M. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin. Cancer Res. 2000;6:1198–1199. PubMed

Kawata S., Yamasaki E., Nagase T., Inui Y., Ito N., Matsuda Y., Inada M., Tamura S., Noda S., Imai Y., et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer. 2001;84:886–891. doi: 10.1054/bjoc.2000.1716. PubMed DOI PMC

Kim W.S., Kim M.M., Choi H.J., Yoon S.S., Lee M.H., Park K., Park C.H., Kang W.K. Phase II study of high-dose lovastatin in patients with advanced Bystric adenocarcinoma. Incest. New Drugs. 2001;19:81–83. doi: 10.1023/A:1006481423298. PubMed DOI

Larner J., Jane J., Laws E., Packer R., Myers C., Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am. J. Clin. Oncol. 1998;21:579–583. doi: 10.1097/00000421-199812000-00010. PubMed DOI

Bonovas S., Filioussi K., Sitaras N.M. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: Evidence from a meta-analysis of 12 studies. Am. J. Gastroenterol. 2008;103:2646–3651. doi: 10.1111/j.1572-0241.2008.02051.x. PubMed DOI

Bonovas S., Filioussi K., Tsantes A., Sitaras N.M. Use of statins and risk of haematological malignancies: A meta-analysis of six randomized clinical trials and eight observational studies. Br. J. Clin. Pharmacol. 2007;64:255–262. doi: 10.1111/j.1365-2125.2007.02959.x. PubMed DOI PMC

Bonovas S., Sitaras N.M. Does pravastatin promote cancer in elderly patients? A metaanalysis. CMAJ. 2007;176:649–654. doi: 10.1503/cmaj.060803. PubMed DOI PMC

Gbelcová H., Rimpelová S., Ruml T., Fenclová M., Kosek V., Hajšlová J., Strnad H., Kolář M., Vítek L. Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Sci. Rep. 2017;7:44219. doi: 10.1038/srep44219. PubMed DOI PMC

Gbelcová H., Leníček M., Zelenka J., Knejzlík Z., Dvořáková G., Zadinová M., Poučková P., Kudla M., Balaž P., Ruml T., et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int. J. Cancer. 2008;122:1214–1221. doi: 10.1002/ijc.23242. PubMed DOI

Longo J., van Leeuwen J.E., Elbaz M., Branchard E., Penn L.Z. Statins as anticancer agents in the era of precision medicine. Clin. Cancer Res. 2020;26:5791–5800. doi: 10.1158/1078-0432.CCR-20-1967. PubMed DOI

Mullen P.J., Yu R., Longo J., Archer M.C., Penn L.Z. The interplay between cell signalling and the mevalonate pathway in cancer. Nat. Rev. Cancer. 2016;16:718–731. doi: 10.1038/nrc.2016.76. PubMed DOI

Di Bello E., Zwergel C., Mai A., Valente S. The innovative potential of statins in cancer: New targets for new therapies. Front. Chem. 2020;8:516. doi: 10.3389/fchem.2020.00516. PubMed DOI PMC

Ahmadi M., Amiri S., Pecic S., Machaj F., Rosik J., Łos M.J., Alizadeh J., Mahdian R., da Silva Rosa S.C., Schaafsma D., et al. Pleiotropic effects of statins: A focus on cancer. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165968. doi: 10.1016/j.bbadis.2020.165968. PubMed DOI

Zhang Y., Liang M., Sun C., Qu G., Shi T., Min M., Wu Y., Sun Y. Statin use and risk of pancreatic cancer an updated meta-analysis of 26 studies. Pancreas. 2019;48:142–150. doi: 10.1097/MPA.0000000000001226. PubMed DOI

Riscal R., Skuli N., Simon M.C. Even cancer cells watch their cholesterol! Mol. Cell. 2019;76:220–231. doi: 10.1016/j.molcel.2019.09.008. PubMed DOI PMC

Zhuang L., Kim J., Adam R.M., Solomon K.R., Freeman M.R. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Investig. 2005;115:959–968. doi: 10.1172/JCI200519935. PubMed DOI PMC

Gordon R.E., Zhang L., Peri S., Kuo Y.M., Du F., Egleston B.L., Ng J.M.Y., Andrews A.J., Astsaturov I., Curran T., et al. Statins synergize with hedgehog pathway inhibitors for treatment of medulloblastoma. Clin. Cancer Res. 2018;24:1375–1388. doi: 10.1158/1078-0432.CCR-17-2923. PubMed DOI PMC

Eaton S. Multiple roles for lipids in the Hedgehog signalling pathway. Nat. Rev. Mol. Cell. Biol. 2008;9:437–445. doi: 10.1038/nrm2414. PubMed DOI

Allen B.L., Tenzen T., McMahon A.P. The hedgehog-binding proteins GAS1 and CDO cooperate to positively regulate SHH signalling during mouse development. Genes Dev. 2007;21:1244–1257. doi: 10.1101/gad.1543607. PubMed DOI PMC

Martinelli D.C., Fan C.M. Gas1 extends the range of hedgehog action by facilitating its signalling. Genes Dev. 2007;21:1231–1243. doi: 10.1101/gad.1546307. PubMed DOI PMC

Shao W., Espenshade P.J. Expanding roles for SREBP in metabolism. Cell Metab. 2012;16:414–419. doi: 10.1016/j.cmet.2012.09.002. PubMed DOI PMC

Li X., Chen Y.T., Hu P., Huang W.C. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol. Cancer Ther. 2014;13:855–866. doi: 10.1158/1535-7163.MCT-13-0797. PubMed DOI PMC

Wen Y.A., Xiong X., Zaytseva Y.Y., Napier D.L., Vallee E., Li A.T., Wang C., Weiss H.L., Evers B.M., Gao T. Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer. Cell Death Dis. 2018;9:265. doi: 10.1038/s41419-018-0330-6. PubMed DOI PMC

Carrer A., Trefely S., Zhao S., Campbell S.L., Norgard R.J., Schultz K.C., Sidoli S., Parris J.L.D., Affronti H.C., Sivanand S., et al. AcetylCoA metabolism supports multistep pancreatic tumorigenesis. Cancer Discov. 2019;9:416–435. doi: 10.1158/2159-8290.CD-18-0567. PubMed DOI PMC

Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005;37:391–400. doi: 10.1038/ng1531. PubMed DOI

Sahai E., Marshall C.J. Rho-GTPases and cancer. Nat. Rev. Cancer. 2002;21:133–142. doi: 10.1038/nrc725. PubMed DOI

Ridley A.J. Rho proteins and cancer. Breast Cancer Res. Treat. 2004;84:13–19. doi: 10.1023/B:BREA.0000018423.47497.c6. PubMed DOI

Mazieres J., Tillement V., Allal C., Clanet C., Bobin L., Chen Z., Sebti S.M., Favre G., Pradines A. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Exp. Cell Res. 2005;304:354–364. doi: 10.1016/j.yexcr.2004.10.019. PubMed DOI

Prendergast G.C. Actin’ up: RhoB in cancer and apoptosis. Nat. Rev. Cancer. 2001;1:162–168. doi: 10.1038/35101096. PubMed DOI

Furuhjelm J., Peränen J. The C-terminal end of R-Ras contains a focal adhesion targeting signal. J. Cell Sci. 2003;116:3729–3738. doi: 10.1242/jcs.00689. PubMed DOI

Nowak J., Archange C., Tardivel-Lacombe J., Pontarotti P., Pébusque M.J., Vaccaro M.I., Velasco G., Dagorn J.C., Iovanna J.L. The TP53INP2 protein is required for autophagy in mammalian cells. Mol. Biol. Cell. 2008;20:870–881. doi: 10.1091/mbc.e08-07-0671. PubMed DOI PMC

NCBI. [(accessed on 9 February 2021)]; Available online: https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=4998.

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=983.

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=994.

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=6502.

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=1870.

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=8793.

Corpataux J.M., Naik J., Porter K.E., London N.J. The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. J. Surg. Res. 2005;129:52–56. doi: 10.1016/j.jss.2005.05.016. PubMed DOI

Fromigue O., Hamidouche Z., Vaudin P., Lecanda F., Patino A., Barbry P., Mari B., Marie P.J. CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J. Bone Miner. Res. 2011;26:1533–1542. doi: 10.1002/jbmr.343. PubMed DOI

Kidera Y., Tsubaki M., Yamazoe Y., Shoji K., Nakamura H., Ogaki M., Satou T., Itoh T., Isozaki M., Kaneko J., et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J. Exp. Clin. Cancer Res. 2010;29:127. doi: 10.1186/1756-9966-29-127. PubMed DOI PMC

Brown M., Hart C., Tawadros T., Ramani V., Sangar V., Lau M., Clarke N. The differential effects of statins on the metastatic behaviour of prostate cancer. Br. J. Cancer. 2012;106:1689–1696. doi: 10.1038/bjc.2012.138. PubMed DOI PMC

Wang G., Cao R., Wang Y., Qian G., Dan H.C., Jiang W., Ju J., Wu M., Xiao Y., Wang X. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway. Sci. Rep. 2016;6:35783. doi: 10.1038/srep35783. PubMed DOI PMC

Sheng S., Barnett D.H., Katzenellenbogen B.S. Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells. Mol. Cell Endocrinol. 2008;296:1–9. doi: 10.1016/j.mce.2008.09.022. PubMed DOI PMC

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=7138.

Sun H.Q., Yamamoto M., Mejillano M., Yin H.L. Gelsolin, a multifunctional actin regulatory protein. J. Biol. Chem. 1999;274:33179–33182. doi: 10.1074/jbc.274.47.33179. PubMed DOI

Schnitzer M.J., Block S.M. Kinesin hydrolyses one ATP per 8-nm step. Nature. 1997;388:386–390. doi: 10.1038/41111. PubMed DOI

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=3728.

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=7430.

NCBI. [(accessed on 9 February 2021)]; Available online: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=1008.

Durinck S., Moreau Y., Kasprzyk A., Davis S., De Moor B., Brazma A., Huber W. BioMart and Bioconductor: A powerful link between biological databases and microarray data analysis. Bioinformatics. 2005;21:3439–3440. doi: 10.1093/bioinformatics/bti525. PubMed DOI

Hubbard J.P., Aken B.L., Beal K., Ballester B., Caccamo M., Chen Y., Clarke L., Coates G., Cunningham F., Cutts T., et al. Ensembl 2007. Nuc. Acids Res. 2007;35:D610–D617. doi: 10.1093/nar/gkl996. PubMed DOI PMC

Luo W., Brouwer C. Pathview: An R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013;29:1830–1831. doi: 10.1093/bioinformatics/btt285. PubMed DOI PMC

Kanehisa M., Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucl. Acids Res. 2000;28:27–30. doi: 10.1093/nar/28.1.27. PubMed DOI PMC

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

R Core Team R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing; Vienna, Austria. [(accessed on 20 February 2021)]; Available online: https://www.R-project.org/

Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034.1. doi: 10.1186/gb-2002-3-7-research0034. PubMed DOI PMC

STRING. [(accessed on 9 February 2021)]; Available online: https://string-db.org/

Stocker R., Bowry V.W., Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than doe’s α-tocopherol. Med. Sci. 1991;88:1646–1650. doi: 10.1073/pnas.88.5.1646. PubMed DOI PMC

Wong W.W., Clendening J.W., Martirosyan A., Boutros P.C., Bros C., Khosravi F., Jurisica I., Stewart A.K., Bergsagel P.L., Penn L.Z. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol. Cancer Ther. 2007;6:1886–1897. doi: 10.1158/1535-7163.MCT-06-0745. PubMed DOI

Jacobson J.R., Wong W.W., Dimitroulakos J., Minden M.D., Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508–519. doi: 10.1038/sj.leu.2402476. PubMed DOI

Jacobson J.R., Dudek S.M., Birukov K.G., Ye S.Q., Grigoryev D.N., Girgis R.E., Garcia J.G. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am. J. Respir. Cell Mol. Biol. 2004;30:662–670. doi: 10.1165/rcmb.2003-0267OC. PubMed DOI

Johnson-Anuna L.N., Eckert G.P., Keller J.H., Igbavboa U., Franke C., Fechner T., Schubert-Zsilavecz M., Karas M., Müller W.E., Wood W.G. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J. Pharmacol. Exp. Ther. 2005;312:786–793. doi: 10.1124/jpet.104.075028. PubMed DOI

Adamkov M., Halasova E., Rajcani J., Bencat M., Vybohova D., Rybarova S., Galbavy S. Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas. Med. Sci. Monit. 2011;17:BR74–BR80. doi: 10.12659/MSM.881442. PubMed DOI PMC

Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004;18:1272–1282. doi: 10.1101/gad.1199904. PubMed DOI PMC

Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717–1721. doi: 10.1126/science.290.5497.1717. PubMed DOI PMC

Fujimoto T., Ohsaki Y. Proteasomal and autophagic pathways converge on lipid droplets. Autophagy. 2006;2:299–301. doi: 10.4161/auto.2904. PubMed DOI

Yang Y.C., Huang W.F., Chuan L.M., Xiao D.W., Zeng Y.L., Zhou D.A., Xu G.Q., Liu W., Huang B., Hu Q. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemotherapy. 2008;54:438–446. doi: 10.1159/000158663. PubMed DOI

Assmus B., Urbich C., Aicher A., Hofmann W.K., Haendeler J., Rössig L., Spyridopoulos I., Zeiher A.M., Dimmeler S. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res. 2003;92:1049–1055. doi: 10.1161/01.RES.0000070067.64040.7C. PubMed DOI

Denoyelle C., Albanese P., Uzan G., Hong L., Vannier J.P., Soria J., Soria C. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal. 2003;15:327–338. doi: 10.1016/S0898-6568(02)00124-9. PubMed DOI

Keyomarsi K., Sandoval L., Band V., Pardee A.B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602–3609. PubMed

Maltese W.A., Sheridan K.M. Differentiation of neuroblastoma cells induced by an inhibitor of mevalonate synthesis: Relation of neurite outgrowth and acetylcholinesterase activity to changes in cell proliferation and blocked isoprenoid synthesis. J. Cell Physiol. 1985;125:540–558. doi: 10.1002/jcp.1041250326. PubMed DOI

Jakóbisiak M., Bruno S., Skierski J.S., Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA. 1991;88:3628–3632. doi: 10.1073/pnas.88.9.3628. PubMed DOI PMC

Ghosh P.M., Mott G.E., Ghosh-Choudhury N., Radnik R.A., Stapleton M.L., Ghidoni J.J., Kreisberg J.I. Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochim. Biophys. Acta. 1997;1359:13–24. doi: 10.1016/S0167-4889(97)00091-8. PubMed DOI

Engelke K.J., Hacker M.P. A non-characteristic response of L1210 cells to lovastatin. Biochem. Biophys. Res. Commun. 1994;203:400–407. doi: 10.1006/bbrc.1994.2196. PubMed DOI

Rao S., Porter D.C., Chen X., Herliczek T., Lowe M., Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA. 1999;96:7797–7802. doi: 10.1073/pnas.96.14.7797. PubMed DOI PMC

Cooper S. Reappraisal of G1-phase arrest and synchronization by lovastatin. Cell Biol. Int. 2002;26:715–727. doi: 10.1006/cbir.2002.0925. PubMed DOI

da Costa R.F., Freire V.N., Bezerra E.M., Cavada B.S., Caetano E.W., de Lima Filho J.L., Albuquerque E.L. Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations. Phys. Chem. Chem. Phys. 2012;14:1389–1398. doi: 10.1039/C1CP22824B. PubMed DOI

Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160–1164. doi: 10.1126/science.1059344. PubMed DOI

Mück W., Ritter W., Ochmann K., Unger S., Ahr G., Wingender W., Kuhlmann J. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int. J. Clin. Pharmacol. Ther. 1997;35:255–260. PubMed

Kajinami K., Mabuchi H., Saito Y. NK-104: A novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Investig. Drugs. 2000;9:2653–2661. doi: 10.1517/13543784.9.11.2653. PubMed DOI

Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 1998;19:26–37. doi: 10.1016/S0165-6147(97)01147-4. PubMed DOI

Menter D.G., Ramsauer V.P., Harirforoosh S., Chakraborty K., Yang P., Hsi L., Newman R.A., Krishnan K. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS ONE. 2011;6:e28813. doi: 10.1371/journal.pone.0028813. PubMed DOI PMC

Hindler K., Cleeland C.S., Rivera E., Collard C.D. The role of statins in cancer therapy. Oncologist. 2006;11:306–315. doi: 10.1634/theoncologist.11-3-306. PubMed DOI

Chimento A., Casaburi I., Avena P., Trotta F., De Luca A., Rago V., Pezzi V., Sirianni R. Cholesterol and its metabolites in tumor growth: Therapeutic potential of statins in cancer treatment. Front Endocrinol. (Lausanne) 2019;9:807. doi: 10.3389/fendo.2018.00807. PubMed DOI PMC

Sopková J., Vidomanová E., Strnádel J., Škovierová H., Halašová E. The role of statins as therapeutic agents in cancer. Gen. Phys. Biophys. 2017;36:501–511. doi: 10.4149/gpb_2017045. PubMed DOI

Highly variable biological effects of statins on cancer, non-cancer, and stem cells in vitro